



# SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.  
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

**Ref: SPL/CORP-SEC/2022-23/BSE/232**

**Dated:12.08.2022**

**To,**

Bombay Stock Exchange Ltd,  
Phirojshah Jeejobhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

**Sub: Outcome of the Board Meeting with Scrip Code 524703.**

A Meeting of the Board of Directors of the Company duly convened on Friday, 12<sup>th</sup> August 2022 at 05:00 p.m. and concluded at 06:05 p.m. discussed the following business: -

1. Considered, Approved and took on record Unaudited Financial Results for the Quarter 30<sup>th</sup> June 2022.
2. Approved Directors Report, Management Discussion and Analysis Report, Corporate Governance Report, Secretarial Audit Report etc for the year ended 31<sup>st</sup> March 2022.
3. Recommended Dividend of Rs 0.75 Paise/- per Equity Shares(i.e 0.75% on paid up Share Capital of the Company) having face value of Rs 10/- each for the Financial Year ended 31<sup>st</sup> March 2022, upon approval of the final dividend by the Shareholders at the 37<sup>th</sup> Annual General Meeting, the dividend amount after deducting applicable TDS, will be credited to the Bank Accounts of the Shareholders who have registered their Bank Account details with the Depository/ Company and for those Shareholders who have not registered their Bank Account details, dividend warrants will be dispatched on or before 25<sup>th</sup> October 2022.
4. To close Register of Members and Share Transfer Books of the Company from Saturday, 24<sup>th</sup> September 2022 to Friday, 30<sup>th</sup> September 2022 both days inclusive.
5. To convene the 37<sup>th</sup> Annual General Meeting of the Company on Friday, the 30<sup>th</sup> September 2022 at 04:30 pm in video conferencing/other AudioVisual Means, details on the manner of attending the AGM and casting votes by Shareholders will be set out in the Notice of the AGM.
6. Took note of Statement of Utilizations and Deviations as per Regulation 32 of SEBI (LODR) Regulation 2015 for the Quarter ended 30<sup>th</sup> June 2022.

You are requested to kindly take the same on record.

Yours Faithfully,



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.  
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587





# SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.  
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

**FOR SANDU PHARMACEUTICALS LTD.**



Pratika Mhambray  
Company Secretary




**AN ISO 9001:2008 CERTIFIED ORGANISATION**

**Corporate Office:** P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.  
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

**CIN: L24233GA1985PLC001587**



Sandu Pharmaceuticals Ltd					
STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 30/06/22					
					( Rs in Lakhs )
	Particulars	Qtr Ending June 2022	Qtr Ending March 2022	Qtr Ending June 2021	Year Ended March 2022
		(Un audited)	(Audited)	(Un Audited)	(Audited)
I	Revenue From Operations	1,622.85	1,142.40	1,733.59	6,550.05
II	Other Income	8.59	2.78	2.34	8.28
III	Total Income (I+II)	1,631.44	1,145.18	1,735.93	6,558.33
IV	<b>EXPENSES</b>				
	Cost of materials consumed	230.60	283.86	259.65	1,419.58
	Purchases of Stock-in-Trade	821.47	43.56	676.95	2,200.13
	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	(177.86)	37.94	148.04	(45.43)
	Employee benefits expense	239.34	183.75	216.84	891.21
	Finance costs	2.29	2.09	3.83	11.00
	Depreciation and amortization expense	12.56	13.13	13.19	53.01
	Other expenses	476.58	535.91	358.97	1,797.15
	<b>Total expenses (IV)</b>	<b>1,604.97</b>	<b>1,100.24</b>	<b>1,677.47</b>	<b>6,326.65</b>
V	Profit/(loss) before exceptional items and tax (I- IV)	26.48	44.94	58.46	231.68
VI	Exceptional Items			-	-
VII	Profit/(loss) before tax (V-VI)	26.48	44.94	58.46	231.68
VIII	Tax expense:				
	(1) Current tax	8.15	14.69	16.27	69.60
	(2) Deferred tax	0.16	3.31	0.37	3.13
	Short / ( Excess ) Tax Provision	1.25			-
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	16.93	26.94	41.82	158.95
X	Profit/(loss) for the period (IX+XII)	16.93	26.94	41.82	158.95
XI	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss				
	a. Remeasurement gains/(losses) on post employment defined benefit plans		3.62		3.62
	b. Fair value changes of investments	26.17	(0.93)	5.98	28.38
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(2.91)	8.01	(0.66)	4.75
	B (i) Items that will be reclassified to profit or loss	-		-	
	(ii) Income tax relating to items that will be reclassified to profit or loss				
XII	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	40.19	37.64	47.14	195.70
XIV	Paid Up Equity Capital ( Face Value of Rs 10/- Per share )	881.06	881.06	792.09	881.06



XVI

Earnings per equity share (for continuing

operation):

(1) Basic


(2) Diluted

0.19	0.34	0.53	1.99	
0.18	0.31	0.48	1.87	

Place :- Mumbai  
Date :- 12/08/2022

For Sandu Pharmaceuticals Ltd

Umesh Sandu  
Managing Director  
DIN :- 01132141







1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 12<sup>th</sup> August, 2022. The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Proprietary Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
3. The Company has considered the possible impact of COVID 19 pandemic on its operations, liquidity position and recoverability of its assets balances at 30<sup>th</sup> June, 2022 based on the internal and external information up to the date of approval of these financial results. The impact of COVID 19 may be different from that estimated as at the time of approval of these financial results and management will continue to monitor any material changes arising due to the impact of this pandemic on financial and operational performance of the company and take necessary measures to address the situation.
4. The Figures for the quarter ended 31 st March, 2022 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.
6. The Above results are reviewed and recommended by the audit committee and Approved by Board of Directors at the meeting held on 12<sup>th</sup> August, 2022 and there are No qualification in the audit report for the quarter ended, 30<sup>th</sup> June, 2022.

Date: - 12/08/2022

For Sandu Pharmaceuticals Ltd



Umesh Sandu  
Managing Director  
DIN: - 01132141





**Dileep & Prithvi**

CHARTERED ACCOUNTANTS

**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL  
RESULTS FOR THE QUARTER ENDED ON 30th JUNE, 2022**

To,

**The Board of Directors,  
Sandu Pharmaceuticals Limited,  
Plot No. 25, 26, 29 & 30,  
Pilerne Industrial Estate, Marra,  
Bardez, Goa-403511.**

Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter ended on 30<sup>th</sup> June, 2022, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (*SRE*) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Dileep & Prithvi**

Chartered Accountants

Firm Registration Number: 122290W

**Himmat Mali**

(Partner)

Membership Number: 183378

UDIN-22183378AOWJRN1934



Place: Mumbai  
Date: 12<sup>th</sup> August, 2022